ovarian cancer Archives - PharmaDeviceNews

Why Gilead’s $5bn Tubulis deal could reshape its solid tumour pipeline strategy

Gilead’s Tubulis deal strengthens its ADC pipeline, but oncology execution, safety and clinical proof now decide the upside.

PARP selection still leaves gaps. Inocras’ WGS-HRD data suggest whole-genome testing may refine ovarian cancer maintenance decisions.

CDH6 ADCs are heating up. OnCusp Therapeutics now needs capital discipline to turn CUSP06 promise into clinical and investor credibility.

Find out how Epitopea’s CryptiVax-1001 trial could reshape RNA cancer vaccines and ovarian cancer treatment strategies.

Palleon Pharmaceuticals has moved E-688/HLX316 into human testing. Read why this B7-H3 sialidase could reshape immuno-oncology.

Debiopharm’s ovarian cancer combo won FDA Fast Track after AACR 2026 data. Read what it means for DDR therapy, biomarkers, and clinical risk.

Read how SAGA Diagnostics’ AACR 2026 Pathlight data could reshape ctDNA monitoring in metastatic breast and ovarian cancer.

Whitehawk Therapeutics says new MUC16 data support HWK-016 in gynecologic cancers. Read what this could change for ADC development.

Zentalis Pharmaceuticals advances azenosertib through DENALI and ASPENOVA. Read what this means for ovarian cancer strategy and approval risk.

Gilead is acquiring Tubulis to expand its antibody-drug conjugate pipeline. Read what the deal changes for oncology strategy and ADC competition.